Recursion Pharmaceuticals
RXRX
RXRX
192 hedge funds and large institutions have $1.16B invested in Recursion Pharmaceuticals in 2023 Q3 according to their latest regulatory filings, with 56 funds opening new positions, 74 increasing their positions, 38 reducing their positions, and 20 closing their positions.
New
Increased
Maintained
Reduced
Closed
more first-time investments, than exits
New positions opened: | Existing positions closed:
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
more capital invested
Capital invested by funds: $ → $
more funds holding
Funds holding: →
5.54% more ownership
Funds ownership: 69.08% → 74.62% (+5.5%)
3% less call options, than puts
Call options by funds: $5.88M | Put options by funds: $6.09M
17% less funds holding in top 10
Funds holding in top 10: 6 → 5 (-1)
Holders
192
Holding in Top 10
5
Calls
$5.88M
Puts
$6.09M
Top Buyers
| 1 | +$46.9M | |
| 2 | +$46.4M | |
| 3 | +$32.5M | |
| 4 |
NAMA
Nikko Asset Management Americas
New York
|
+$20.5M |
| 5 |
Sumitomo Mitsui Trust Group
Minato-Ku, Tokyo,
Japan
|
+$20.5M |
Top Sellers
| 1 | -$17.4M | |
| 2 | -$9.05M | |
| 3 | -$8.77M | |
| 4 |
HMC
Harvard Management Company
Boston,
Massachusetts
|
-$6.59M |
| 5 |
Balyasny Asset Management
Chicago,
Illinois
|
-$5.98M |